Method for determining associativity of active component of pachyrhizus fortunei decoction and WD-copper death target gene

Through bioinformatics and clinical verification, combining the binding of the active ingredients of Gando Fumu Decoction with the WD-copper death target gene, the target recognition problem in liver bean-like nuclear degeneration diseases has been solved, and new treatment ideas and directions have been provided. , a new method for diagnosis and treatment of WD patients has been realized.

CN119068983AActive Publication Date: 2024-12-03FIRST AFFILIATED HOSPITAL OF ANHUI UNIV OF CHINESE MEDICINE
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202411059500.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-04
Publication Date
2024-12-03
Estimated Expiration
2044-08-04

AI Technical Summary

Technical Problem

The prior art is difficult to effectively identify and verify target genes related to copper death in hepato-like nuclear degeneration diseases, which limits the treatment ideas and directions of the disease.

Method used

By combining bioinformatics analysis and clinical verification, the binding of the active ingredient of Gando Fumu Soup with WD-copper death target gene was screened out. WD-copper was determined by using GeneCards, GEO database, Western Blot, qRT-PCR and other methods. The target gene and its expression level were killed, and the binding ability of Gando Fumu Decoction to the target gene was verified through molecular docking.

Benefits of technology

The expression level of copper death target genes in WD patients and the binding of the active ingredients of Gando Fumu Decoction with the target genes were successfully determined, providing new ideas and directions for the diagnosis and treatment of hepato-shaped nuclear degeneration diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119068983A_ABST
    Figure CN119068983A_ABST
Patent Text Reader

Abstract

The method comprises the following steps: establishing a method for combining the active ingredients of the liver-bean-fortune euonymus decoction with a WD-copper death target gene, obtaining differential genes of a WD patient and a normal person through a database, obtaining a copper death related gene by utilizing the database and published documents, and taking an intersection to obtain a WD-copper death target gene. Serum of a healthy control group and serum of a WD patient before and after treatment are collected, the expression level of the target gene is verified through WB and qRT-PCR, and the reasonability of the screened WD-copper death target gene is determined; the copper death target gene expression level of a WD patient is basically consistent with the expression condition of the screened gene. By means of molecular docking and a PyMOL visual analysis technology, common target genes, namely PDK1, SERPINE1, VEGF-A and AOC3, of death of the liver-bean euonymus japonicus soup and WD-copper are determined, and the common target genes have good associativity. Therefore, the copper death mechanism can provide a new target / direction for diagnosis / treatment of WD.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of disease bioinformatics analysis and verification of hepatolenticular degeneration, and in particular to a method for establishing the binding property of an active ingredient of Gandoufumu decoction with a WD-copper death target gene. Background Art

[0002] Hepatolenticular degeneration (HLD), also known as Wilson's disease (WD), is a hereditary copper metabolism disorder that causes liver cirrhosis and brain degeneration mainly in the basal ganglia. ATP7B gene mutation is the main cause of this disease. Its expression product, P-type copper transporter ATPase, loses its function partially or completely, and cannot convert excess copper ions (Cu 2+ ) is transported out of the cell, making the excess Cu 2+ It is deposited in the liver, brain, kidney, cornea and other tissues and causes disease; clinical features include progressive aggravation of extrapyramidal symptoms, mental symptoms, liver cirrhosis, renal impairment and corneal pigment rings. The treatment principle for this disease is to adopt a low-copper diet and use drugs to reduce copper absorption and increase copper excretion. Commonly used drugs include zinc, ammonium tetramercaptomolybdate, D-penicillamine, sodium dithiopropanesulfonate, etc.

[0003] Copper death is a Cu 2+ A regulated cell death pathway that is dependent on Cu 2+ By directly binding to the acylated part of the tricarboxylic acid cycle, it induces the aggregation of acylated proteins and the instability of iron-sulfur cluster proteins, leading to proteotoxic stress and thus inducing cell death. Peter Tsvetkov et al. found that the cellular effects caused by WD copper overload were the same as those induced by copper death, manifested as the aggregation of acylated proteins and the instability of iron-sulfur cluster proteins; Xu Lewen et al. found that lipoylation-related proteins and iron-sulfur protein deficiency jointly induced WD mitochondrial damage to further induce cell death.

[0004] At present, the Chinese medicine Gandoufumu Decoction, which is composed of white peony root, wolfberry, bupleurum, turmeric, smilax glabra, and Panax notoginseng, has a good therapeutic effect on Wilson's disease. The present invention aims to study and identify copper death-related genes that are differentially expressed in WD, and provide new gene targets for the treatment of the disease. Bioinformatics methods are used to screen WD-copper death target genes, analyze the biological processes, functions or metabolic pathways involved, and screen copper death target genes in the occurrence and development of WD by analyzing existing disease and patient data sets from different angles and conducting clinical verification. Summary of the invention

[0005] The purpose of the present invention is to propose a method for establishing the binding of the active ingredients of Gandoufumu Decoction to the WD-copper death target gene, to explore the role of copper death in the occurrence and development of WD through bioinformatics analysis and clinical verification of WD-copper death-related genes, and then to determine the key targets, providing new ideas and directions for the diagnosis and treatment of WD.

[0006] In order to achieve the above object, the technical solution adopted by the present invention is:

[0007] The method for establishing the binding of the active ingredients of Gandoufumu Decoction to the WD-copper death target gene comprises the following steps:

[0008] Step S1, Screening of WD-copper death target genes:

[0009] The differentially expressed genes between WD patients and normal subjects were obtained through the GeneCards database, and the copper-related death genes were obtained from the Gene Expression Omnibus (GEO) database and published literature, and the WD-copper death target genes were obtained by taking the intersection.

[0010] Step S2, verification of WD-copper death target genes:

[0011] Serum was collected from healthy controls and WD patients before and after treatment, and the expression levels of target genes were verified by Western Blot and qRT-PCR to determine the rationality of the screened WD-copper death target genes;

[0012] Step S3, molecular docking verification and visualization analysis of Gandoufumu Decoction and WD-copper death target gene:

[0013] By using molecular docking and PyMOL visualization analysis technology, the common target genes of the active ingredients of Gandou Fumu Tang and WD-copper death were established, and the binding between the two was analyzed.

[0014] As a preferred technical solution of the present invention, the specific steps of step S1 are as follows:

[0015] Step S11, obtaining copper death-related genes:

[0016] Using "Cuproptosis" as the keyword, we mined the corresponding human disease gene targets using the GeneCards database, and obtained known Cuproptosis-related genes by searching the literature, and summarized the Cuproptosis-related genes.

[0017] Step S12, screening WD-copper death target genes:

[0018] The GSE107323 dataset in the Gene Expression Omnibus (GEO) database was used to analyze differentially expressed genes using the GEO2R dataset. P<0.05 and |log2FC|>1 were used as the identification criteria for differentially expressed genes. The target genes of WD-copper death were obtained through the venny plot, of which 3 were up-regulated genes, namely SQSTM1, MIF1, and TAX1BP1; and 9 were down-regulated genes, namely CP, SERPINE1, AOC3, GPX4, SLC27A5, VEGF-A, PDHB, PDK1, and ATP7B.

[0019] Step S13, GO function and KEGG enrichment analysis of WD-copper death target genes:

[0020] The Metascape database was used to perform gene ontology (GO) functional analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment pathway analysis on the WD-copper death target genes. GO analysis included cellular component (CC), molecular function (MF), and biological process (BP). KEGG was used to screen important signal pathways, and the screening condition was P<0.05.

[0021] As a preferred technical solution of the present invention, the specific steps of step S2 are as follows:

[0022] Step S21, collecting about 5 ml of fasting peripheral venous blood from the healthy control group and the patient group before and after treatment, and centrifuging using a H1850 medical centrifuge to obtain serum;

[0023] Step S22, WB (Western Blot) relative expression detection:

[0024] To detect the expression of CP, SQSTM1, MIF1, TAX1BP1, SERPINE1, AOC3, GPX4, SLC27A5, VEGF-A, PDHB, and PDK1 proteins, appropriate amount of serum samples were weighed, 600 μl of RIPA protein lysis buffer was added for full lysis, protein was extracted, sample buffer was added, and denaturation was carried out in a boiling water bath for 15 min; SDS-PAGE electrophoresis was performed, transferred to PVDF membrane, and blocked with 5% skim milk powder for 2 h; CP, SQSTM1, MIF1, TAX1BP1, SERPINE1, AOC3, GPX4, SLC27A5, VEGF-A, PDHB, and PDK1 antibodies were added, incubated at 4°C overnight, secondary antibodies were added after rinsing, blocked at room temperature for 1.2 h, ECL reaction was added, and development was performed after exposure, and the bands were analyzed with β-actin and GAPDH as internal references;

[0025] Step S23, qRT-PCR verification:

[0026] The mRNA expressions of CP, SQSTM1, MIF1, TAX1BP1, SERPINE1, AOC3, GPX4, SLC27A5, VEGF-A, PDHB and PDK1 in serum samples were detected. Appropriate amount of serum samples were weighed and RNA was extracted by Trizol. 1 μL RNA sample was taken as template and reverse transcribed to obtain cDNA. The corresponding fluorescence quantitative PCR reaction parameters were set with cDNA as template: 95°C, 5 min, 95°C, 10 s, 60°C, 30 s, 40 cycles. The Ct value was obtained according to the amplification curve. -ΔΔCt Calculate the relative expression.

[0027] As a preferred technical solution of the present invention, the specific steps of step S3 are as follows:

[0028] Step S31, using the TCMSP database to search for active ingredients of Gandoufumu Decoction respectively, and further screening based on oral bioavailability (OB) ≥ 30% and drug-like property (DL) ≥ 0.18;

[0029] Step S32, obtaining the gene target of the screened component through the herb database and Swisstarget platform; inputting the target name in the Uniport database, finding the Entry, inputting the Entry number in the PDB database, searching and downloading the PDB file that meets the conditions;

[0030] Step S33, search for the InCheky of the active ingredient in the TCMSP database and input it into Pubchem, download the 3D structure file of the compound; import the ligand and receptor into the CB-DOCK2 website for molecular docking and test the binding ability. Affinity <-5.0 kcal / mol indicates that there is a certain binding activity between the ingredient and the receptor protein. The smaller the binding energy, the stronger the binding activity.

[0031] The present invention explores the role of copper death in the occurrence and development of WD by performing bioinformatics analysis and clinical verification on WD-copper death-related genes, and further determines key targets, providing new ideas and directions for the diagnosis and treatment of WD.

[0032] Compared with the prior art, the beneficial effects of the present invention are as follows:

[0033] (1) A total of 3607 WD differentially expressed genes were obtained using the GSE107323 dataset in the Gene Expression Omnibus (GEO) database. A total of 68 copper death-related genes were obtained through the GeneCards database and published literature. The intersection of WD differentially expressed genes and copper death genes was used to obtain 12 WD-copper death target genes, including 3 up-regulated genes (SQSTM1, MIF1, TAX1BP1) and 9 down-regulated genes (CP, SERPINE1, AOC3, GPX4, SLC27A5, VEGF-A, PDHB, PDK1, ATP7B). GO function and KEGG enrichment analysis showed that WD-copper death target genes were mainly involved in metabolic processes such as monocarboxylate metabolism, oxidoreductase activity, and negative regulation of molecular functions, involving signaling pathways such as HIF-1 and Ferroptosis.

[0034] (2) A total of 30 clinical blood samples were collected, including 15 WD patients and 15 healthy people. The WB results showed that the expression levels of the target genes were consistent with the gene expression obtained by screening; RT-qPCR results showed that compared with the healthy control group, the expression levels of SERPINE1, GPX4, SLC27A5, and VEGF-A mRNA in WD patients were lower, while SQSTM1 and MIF1 mRNA were at higher levels.

[0035] (3) Molecular docking and visualization analysis showed that Gandoufumu Decoction had good binding ability with the target genes of WD-copper death, PDK1, SERPINE1, VEGF-A, and AOC3.

[0036] The present invention finally determined that Gandoufumu Decoction has good binding with the common target genes of WD-copper death-PDK1, SERPINE1, VEGF-A, and AOC3. The expression level of copper death target genes in WD patients is basically consistent with the gene expression obtained by screening. Gandoufumu Decoction, a special preparation of Xin'an Medicine, shows good binding ability with WD-copper death target genes; the copper death mechanism may play a key role in the pathophysiological mechanism of WD, and can provide new targets / directions for the diagnosis / treatment of WD. BRIEF DESCRIPTION OF THE DRAWINGS

[0037] Figure 1 The Venn diagram (a) and volcano diagram (b) of WD-copper death target genes.

[0038] Figure 2 GO function (a) and KEGG enrichment (b) analysis of WD-copper death target genes.

[0039] Figure 3 This is the WB relative expression analysis of the target gene.

[0040] Figure 4 This is the relative expression analysis of the target gene by qRT-PCR.

[0041] Figure 5 This is a molecular docking analysis diagram of the active ingredients of Gandoufumu Decoction and the target gene of WD-copper death. Among them, A represents the docking of SERPINE1 with Ginsenoside F2; B represents the docking of PDK1 with Ginsenoside F2; C represents the docking of ACO3 with Benzoylpaeoniflorin; D represents the docking of VEGF-A with Lactiflorin. DETAILED DESCRIPTION

[0042] The present invention is further described in detail below in conjunction with embodiments and drawings.

[0043] 1 Materials and methods

[0044] 1.1 Screening of WD-copper death target genes

[0045] 1.1.1 Obtaining copper death-related genes

[0046] Using "Cuproptosis" as the keyword, the GeneCards (https: / / www.genecards.org / ) database was used to mine the corresponding human disease gene targets, and the known Cuproptosis-related genes were obtained by querying the literature, and the Cuproptosis-related genes were summarized.

[0047] 1.1.2 Screening of WD-copper death target genes

[0048] The GSE107323 dataset in the Gene Expression Omnibus (GEO) database (https: / / www.ncbi.nlm.nih.gov / geo / ) was used (the dataset contained a total of 12 samples, 3 wild-type HepG2 cell lines were selected as controls, and the copper-induced ATP7B gene knockout HepG2 cell line was used for subsequent analysis). The GEO2R (https: / / www.ncbi.nlm.nih.-gov / gen / geo2r / ) dataset was used for differential gene analysis, with P < 0.05 and |log2FC| > 1 as the identification criteria for differential genes, and the target genes of WD-copper death were obtained through the Venny plot.

[0049] 1.1.3GO function and KEGG enrichment analysis of WD-copper death target genes

[0050] Metascape database (https: / / metascape.org / gp / index.html / ) was used to perform gene ontology (GO) functional analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment pathway analysis on WD-copper death target genes, where GO analysis included cellular component (CC), molecular function (MF), and biological process (BP); KEGG was used to screen important signaling pathways. The screening condition was P < 0.05.

[0051] 1.2 Validation of WD-copper death target genes

[0052] 1.2.1 General Information

[0053] From January 2023 to December 2023, 15 patients with WD were admitted to the Department of Neurology of the First Affiliated Hospital of Anhui University of Chinese Medicine, including 7 males (46.67%) and 53.33% females; the patients were aged 17-33 years, with an average age of (25.33±6.28) years; the course of disease was 0.01-20 years, with an average course of disease of (8.17±6.36) years; the clinical classification was mainly liver type in 7 cases (46.67%), brain type in 4 cases (26.67%), and brain-visceral type in 4 cases (26.67%); the average BMI was (21.74±3.56) kg / m 2 .

[0054] Table 1 Comparison of clinical data of enrolled patients ( n=15)

[0055]

[0056]

[0057] 1.2.2 Diagnostic criteria

[0059] 1.2.3 Inclusion criteria

[0060] (1) Any age or gender; (2) Meet the Western medical diagnostic criteria for WD; (3) Have not received formal copper removal treatment before admission; (4) This study was approved by the Medical Ethics Committee of the First Affiliated Hospital of Anhui University of Traditional Chinese Medicine (approval number: 2023AH-03), and the patients or their family members voluntarily participated in the clinical trial and signed a written informed consent.

[0061] 1.2.4 Exclusion criteria

[0062] (1) Patients who have been diagnosed with and received regular copper removal treatment; (2) Patients with fulminant liver failure (with or without hemolytic anemia); (3) Patients with concurrent cognitive dysfunction (Mini-Mental State Examination score ≤ 22 points or Montreal Cognitive Assessment score < 26 points); (4) Patients with concurrent severe neurological impairment such as torsion spasm; (5) Patients with concomitant serious diseases (such as opportunistic infections, tumors, and blood system diseases); (6) Pregnant and lactating women.

[0063] 1.2.6 Observation indicators

[0064] About 5 ml of fasting peripheral venous blood was collected from the healthy control group and patients before and after treatment, and serum was obtained by centrifugation using a H1850 medical centrifuge (Hunan Xiangyi Laboratory Instrument Development Co., Ltd.).

[0065] 1) Western Blot: Detect the expression of CP, SQSTM1, MIF1, TAX1BP1, SERPINE1, AOC3, GPX4, SLC27A5, VEGF-A, PDHB, and PDK1 proteins. Weigh an appropriate amount of serum sample, add 600 μl of RIPA protein lysis buffer to fully lyse, extract the protein, add sample buffer, and denature in a boiling water bath for 15 minutes. Use SDS-PAGE electrophoresis, transfer to PVDF membrane, and block with 5% skim milk powder for 2 hours. Add CP, SQSTM1, MIF1, TAX1BP1, SERPINE1, AOC3, GPX4, SLC27A5, VEGF-A, PDHB, and PDK1 antibodies, incubate overnight at 4°C, add secondary antibodies after rinsing, block at room temperature for 1.2 hours, add ECL reaction, develop after exposure, and analyze the bands with β-actin and GAPDH as internal references.

[0066] 2) qRT-PCR: Detect the mRNA expression of CP, SQSTM1, MIF1, TAX1BP1, SERPINE1, AOC3, GPX4, SLC27A5, VEGF-A, PDHB, and PDK1 in serum samples. Weigh an appropriate amount of serum samples and extract RNA with Trizol. Take 1 μL RNA sample as a template and reverse transcribe to obtain cDNA. Use cDNA as a template and set the corresponding fluorescence quantitative PCR reaction parameters: 95°C, 5 min, 95°C, 10 s, 60°C, 30 s, 40 cycles. According to the amplification curve, the Ct value is obtained. Use 2 -ΔΔCt Calculate the relative expression.

[0067] 1.3 Molecular docking verification and visualization analysis of Gandoufumu decoction and WD-copper death target gene

[0068] The active ingredients of Gandoufumu Decoction were searched by TCMSP database, and oral bioavailability (OB) ≥ 30% and drug-likeness (DL) ≥ 0.18 were further screened. Gene targets of the screened ingredients were obtained through the herb database (http: / / herb.ac.cn / ) and Swisstarget platform (http: / / swisstargetprediction.ch / ). Enter the target name in the Uniport (https: / / www.uniprot.org / ) database, find the Entry, and enter the Entry number in the PDB database to find and download the PDB file that meets the conditions. In the TCMSP database, search for the InCheky of the active ingredient and enter it in Pubchem to download the 3D structure file of the compound. The ligand and receptor were imported into the CB-DOCK2 website (https: / / cadd.labshare.cn / cb-dock2) for molecular docking and testing the binding ability. It is generally believed that affinity <-5.0 kcal / mol indicates that there is a certain binding activity between the ingredient and the receptor protein. The smaller the binding energy, the stronger the binding activity.

[0069] 2 Results

[0070] 2.1 Target gene screening

[0071] 2.1.1 Acquisition of WD-copper death target genes

[0072] After screening, 68 copper death-related genes and 3607 WD differential genes were obtained from the GeneCards database and published literature, including 1772 down-regulated genes and 1835 up-regulated genes. The venny tool was used to obtain 12 target genes, including 3 up-regulated genes (SQSTM1, MIF1, TAX1BP1) and 9 down-regulated genes (CP, SERPINE1, AOC3, GPX4, SLC27A5, VEGF-A, PDHB, PDK1, ATP7B). Figure 1 , as shown in Table 2.

[0073] Table 2WD-Copper Death Target Genes

[0074]

[0075]

[0076] 2.1.2GO function and KEGG enrichment analysis of WD-copper death target genes

[0077] GO biological function analysis showed that CC mainly involved mitochondria, exosomes, endoplasmic reticulum, autophagosomes, etc., BP involved detoxification reaction, monocarboxylic acid metabolism, negative regulation of molecular function, etc., and MF involved copper ion binding, oxidoreductase activity, etc. KEGG analysis obtained 2 entries, mainly involving HIF-1, Ferroptosis and other signaling pathways. Figure 2 , Table 3.

[0078] Table 3 WD-Copper death target gene pathway enrichment analysis

[0079]

[0080] 2.2 Validation of WD-copper death target genes

[0081] 2.2.1WB relative expression

[0082] Compared with the healthy control group, the expression levels of CP, SERPINE1, AOC3, GPX4, SLC27A5, VEGF-A, PDHB, and PDK1 in WD patients were significantly downregulated, and the expression levels of SQSTM1, MIF1, and TAX1BP1 were significantly upregulated (P<0.05). Figure 4 , Table 4.

[0083] Table 4. Relative expression of target genes by WB

[0084]

[0085]

[0086] Note: WD, Wilson's disease; HC, health control; compared with healthy control group # P<0.05.

[0087] 2.2.2 qRT-PCR validation

[0088] Compared with the healthy control group, the mRNA expression levels of CP, SERPINE1, GPX4, SLC27A5, and VEGF-A in WD patients were significantly downregulated, and the mRNA expression levels of SQSTM1 and MIF1 were significantly upregulated (P<0.05). Figure 5 , Table 5.

[0089] Table 5. Relative expression of target genes by qRT-PCR

[0090]

[0091] Note: WD, Wilson's disease; HC, health control; compared with healthy control group # P<0.05

[0092] 2.3 Molecular docking verification and visualization analysis of Gandoufumu decoction and WD-copper death target gene

[0093] The main active ingredients of Gandou Fumu Decoction are:

[0094] Mandenol, Lactiflorin, (E)-5-Hydroxy-7-(4-hydroxyphenyl)-1-phenyl-1-heptene, Quercetin, Paeoniflorin, Benzoyl paeoniflorin, Ginsenoside F2. The results showed that the common target genes of Gandoufumu decoction and WD-copper death were PDK1, SERPINE1, VEGF-A, and AOC3. The molecular docking of the effective active ingredients of Gandoufumu decoction with these WD-copper death target genes had good binding ability. Figure 3 , Table 6.

[0095] Table 6 Analysis of docking of active ingredients of Gandoufumu decoction with WD-copper death target gene molecules

[0096]

[0097] The above contents are merely examples and explanations of the concept of the present invention. The technicians in this technical field may make various modifications or additions to the specific embodiments described or replace them in a similar manner. As long as they do not deviate from the concept of the invention or exceed the scope defined by the claims, they should all fall within the protection scope of the present invention.

Claims

1. Methods to establish the binding of the active ingredients of Gandoufumu Decoction to the WD-copper death target gene, It is characterized in that The steps include: Step S1, Screening of WD-copper death target genes: The differentially expressed genes between WD patients and normal subjects were obtained through the GeneCards database, and the copper-related death genes were obtained from the Gene Expression Omnibus (GEO) database and published literature, and the WD-copper death target genes were obtained by taking the intersection. Step S2, verification of WD-copper death target genes: Serum was collected from healthy controls and WD patients before and after treatment, and the expression levels of target genes were verified by Western Blot and qRT-PCR to determine the rationality of the screened WD-copper death target genes; Step S3, molecular docking verification and visualization analysis of Gandoufumu Decoction and WD-copper death target gene: By using molecular docking and PyMOL visualization analysis technology, the common target genes of the active ingredients of Gandou Fumu Tang and WD-copper death were established, and the binding between the two was analyzed.

2. The method according to claim 1, It is characterized in that The specific steps of step S1 are as follows: Step S11, obtaining copper death-related genes: Using "Cuproptosis" as the keyword, we mined the corresponding human disease gene targets using the GeneCards database, and obtained known Cuproptosis-related genes by searching the literature, and summarized the Cuproptosis-related genes. Step S12, screening WD-copper death target genes: The GSE107323 dataset in the Gene Expression Omnibus (GEO) database was used to analyze differentially expressed genes using the GEO2R dataset. P<0.05 and |log2FC|>1 were used as the identification criteria for differentially expressed genes. The target genes of WD-copper death were obtained through the venny plot, of which 3 were up-regulated genes, namely SQSTM1, MIF1, and TAX1BP1; and 9 were down-regulated genes, namely CP, SERPINE1, AOC3, GPX4, SLC27A5, VEGF-A, PDHB, PDK1, and ATP7B. Step S13, GO function and KEGG enrichment analysis of WD-copper death target genes: The Metascape database was used to perform gene ontology (GO) functional analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment pathway analysis on the WD-copper death target genes. GO analysis included cellular component (CC), molecular function (MF), and biological process (BP). KEGG was used to screen important signal pathways, and the screening condition was P<0.

05.

3. The method according to claim 2, It is characterized in that The specific steps of step S2 are as follows: Step S21, collecting about 5 ml of fasting peripheral venous blood from the healthy control group and the patient group before and after treatment, and centrifuging using a H1850 medical centrifuge to obtain serum; Step S22, WB (Western Blot) relative expression detection: To detect the expression of CP, SQSTM1, MIF1, TAX1BP1, SERPINE1, AOC3, GPX4, SLC27A5, VEGF-A, PDHB, and PDK1 proteins, appropriate amount of serum samples were weighed, 600 μl of RIPA protein lysis buffer was added for full lysis, protein was extracted, sample buffer was added, and denaturation was carried out in a boiling water bath for 15 min; SDS-PAGE electrophoresis was performed, transferred to PVDF membrane, and blocked with 5% skim milk powder for 2 h; CP, SQSTM1, MIF1, TAX1BP1, SERPINE1, AOC3, GPX4, SLC27A5, VEGF-A, PDHB, and PDK1 antibodies were added, incubated at 4°C overnight, secondary antibodies were added after rinsing, blocked at room temperature for 1.2 h, ECL reaction was added, and development was performed after exposure, and the bands were analyzed with β-actin and GAPDH as internal references; Step S23, qRT-PCR verification: The mRNA expressions of CP, SQSTM1, MIF1, TAX1BP1, SERPINE1, AOC3, GPX4, SLC27A5, VEGF-A, PDHB and PDK1 in serum samples were detected. Appropriate amount of serum samples were weighed and RNA was extracted by Trizol. 1 μL RNA sample was taken as template and reverse transcribed to obtain cDNA. The corresponding fluorescence quantitative PCR reaction parameters were set with cDNA as template: 95°C, 5 min, 95°C, 10 s, 60°C, 30 s, 40 cycles. The Ct value was obtained according to the amplification curve. -ΔΔCt Calculate the relative expression.

4. The method according to claim 3, It is characterized in that The specific steps of step S3 are as follows: Step S31, using the TCMSP database to search for active ingredients of Gandoufumu Decoction respectively, and further screening based on oral bioavailability (OB) ≥ 30% and drug-like property (DL) ≥ 0.18; Step S32, obtaining the gene target of the screened component through the herb database and Swisstarget platform; inputting the target name in the Uniport database, finding the Entry, inputting the Entry number in the PDB database, searching and downloading the PDB file that meets the conditions; Step S33, searching for the InCheky of the active ingredient in the TCMSP database and inputting it into Pubchem to download the 3D structure file of the compound; The ligand and receptor were introduced into the CB-DOCK2 website for molecular docking and the binding ability was tested. Affinity < -5.0 kcal / mol indicated that there was a certain binding activity between the component and the receptor protein. The smaller the binding energy, the stronger the binding activity.

5. The method according to claim 4, It is characterized in that Step S3 determined that Gandoufumu Decoction had good binding affinity with the common target genes of WD-copper death - PDK1, SERPINE1, VEGF-A, and AOC3.

Citation Information

Patent Citations

  • Application of reagent for detecting biomarker in preparation of product for predicting gastric cancer prognosis

    CN114875149A

  • Liver cancer prognosis marker screening system and method and liver cancer prognosis risk assessment system

    CN116403643A

  • Application of copper death related gene in diagnosis, treatment and prognosis prediction of adrenocortical carcinoma

    CN117757936A